Print Page    Close Window

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$18.92

0.00 (0.00%)

High$19.00
Low$17.60
Volume0
Market Cap$200,552,851

07/24/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $18.92 with a 52 week high of $19.00 and a 52 week low of $7.25.

Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients

06/28/17

Read More

Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference

06/01/17

Read More

Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch

05/30/17

Read More


There are currently no events scheduled.